22
Bibliography
Bibliography
Bibliography
183
Abrahao AC, Bonelli BV, Nunes FD, Dias EP, Cabral MG. Immunohistochemical expression of p53, p16
and hTERT in oral squamous cell carcinoma and potentially malignant disorders. Braz Oral Res.
2011;25(1):34-41.
Addala L, Kalyan Kumar Ch, Mohan Reddy N, Anjaneyulu V, Sadanani MD. P53 Codon 72 Gene
Polymorphism and Risk of Oral Squamous Cell Carcinoma in South Indian Population: A Case-Control
Study. J Cancer Sci Ther. 2012(b);4(7): 188-92.
Addala L, Pentapati CK, Reddy Thavanati PK, Anjaneyulu V, Sadhnani MD. Risk factor profiles of head
and neck cancer patients of Andhra Pradesh, India. Indian J Cancer. 2012(a);49(2):215-9.
Adduri RS, Katamoni R, Pandilla R, Madana SN, Paripati AK, Kotapalli V, et al. TP53 Pro72 allele is
enriched in oral tongue cancer and frequently mutated in esophageal cancer in India. PLoS One.
2014;9(12):e114002.
Agarwal S, Mathur M, Srivastava A, Ralhan R. MDM2/p53 co-expression in oral premalignant and
malignant lesions: potential prognostic implications. Oral Oncol. 1999;35(2):209-16.
Al-Hadyan KS, Al-Harbi NM, Al-Qahtani SS, Alsbeih GA. Involvement of single-nucleotide
polymorphisms in predisposition to head and neck cancer in Saudi Arabia. Genet Test Mol Biomarkers.
2012;16(2):95-101.
Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis. 2010 Jan;31(1):9-18.
Avigad S, Barel D, Blau O, Malka A, Zoldan M, Mor C, et al. A novel germ line p53 mutation in intron 6 in
diverse childhood malignancies. Oncogene. 1997;14(13):1541-5.
Azzam GA, Frank AK, Hollstein M, Murphy ME. Tissue-specific apoptotic effects of the p53 codon 72
polymorphism in a mouse model. Cell Cycle. 2011;10(9):1352-5.
Bai L, Zhu WG. p53: structure, function and therapeutic applications. J Cancer Mol. 2006;2(4):141-53.
Balaram P, Nalinakumari KR, Abraham E, Balan A, Hareendran NK, Bernard HU, et al. Human
papillomaviruses in 91 oral cancers from Indian betel quid chewers--high prevalence and multiplicity of
infections. Int J Cancer. 1995;61(4):450-4.
Bannikov GA, Karelina TV, Collier IE, Marmer BL, Goldberg GI. Substrate binding of gelatinase B
induces its enzymatic activity in the presence of intact propeptide. J Biol Chem. 2002;277(18):16022-7.
Barros SS, Henriques ÁC, Pereira KM, de Medeiros AM, Galvão HC, Freitas Rde A. Immunohistochemical
expression of matrix metalloproteinases in squamous cell carcinoma of the tongue and lower lip. Arch Oral
Biol. 2011;56(8):752-60.
Beckman G, Birgander R, Själander A, Saha N, Holmberg PA, Kivelä A, Beckman L. Is p53 polymorphism
maintained by natural selection? Hum Hered. 1994;44(5):266-70.
Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, et al. p53 polymorphism influences
response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell. 2003;3(4):387-
402.
Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, et al. Matrix metalloproteinase-9 triggers
the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2(10):737-44.
Bhurgri Y, Bhurgri A, Usman A, Pervez S, Kayani N, Bashir I, et al. Epidemiological review of head and
neck cancers in Karachi. Asian Pac J Cancer Prev. 2006;7(2):195-200.
Bilde A, von Buchwald C, Dabelsteen E, Therkildsen MH, Dabelsteen S. Molecular markers in the surgical
margin of oral carcinomas. J Oral Pathol Med. 2009;38(1):72-8.
Biselli-Chicote PM, Oliveira AR, Pavarino EC, Goloni-Bertollo EM. VEGF gene alternative splicing: pro-
and anti-angiogenic isoforms in cancer. J Cancer Res Clin Oncol. 2012;138(3):363-70.
Bibliography
184
Björklund M, Koivunen E. Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys
Acta. 2005;1755(1):37-69.
Boldrini L, Faviana P, Gisfredi S, Donati V, Zucconi Y, Ursino S, et al. Regulation of telomerase and its
hTERT messenger in colorectal cancer. Oncol Rep. 2004;11(2):395-400.
Bonafé M, Salvioli S, Barbi C, Trapassi C, Tocco F, Storci G, et al. The different apoptotic potential of the
p53 codon 72 alleles increases with age and modulates in vivo ischaemia-induced cell death. Cell Death
Differ. 2004;11(9):962-73.
Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H, et al. MDM2 SNP309 accelerates
tumor formation in a gender-specific and hormone-dependent manner. Cancer Res. 2006;66(10):5104-10.
Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, et al. A single nucleotide polymorphism in
the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in
humans. Cell. 2004;119(5):591-602.
Bond GL, Hu W, Levine AJ. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr
Cancer Drug Targets. 2005;5(1):3-8.
Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's
concept of field cancerization: evidence and clinical implications. Cancer Res. 2003;63(8):1727-30.
Braakhuis BJ, Tabor MP, Leemans CR, van der Waal I, Snow GB, Brakenhoff RH. Second primary tumors
and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and
definitions. Head Neck. 2002;24(2):198-206.
Brennan JA, Mao L, Hruban RH, Boyle JO, Eby YJ, Koch WM, et al. Molecular assessment of
histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med.
1995;332(7):429-35.
Broćić M, Kozomara R, Cerović S, Jović N, Vukelić-Marković S, Stosić S. Clinical significance of vascular
endothelial growth factor expression in patients with carcinoma of the mouth floor and tongue. Vojnosanit
Pregl. 2009;66(6):440-8.
Bu CH, Pourmotabbed T. Mechanism of Ca2+-dependent activity of human neutrophil gelatinase B. J Biol
Chem. 1996;271(24):14308-15.
Byakodi R, Byakodi S, Hiremath S, Byakodi J, Adaki S, Marathe K, et al. Oral cancer in India: an
epidemiologic and clinical review. J Community Health. 2012;37(2):316-9.
Campisi G, Panzarella V, Giuliani M, Lajolo C, Di Fede O, Falaschini S, et al. Human papillomavirus: its
identity and controversial role in oral oncogenesis, premalignant and malignant lesions. Int J Oncol.
2007;30(4):813-23.
Campisi J. Cancer and ageing: rival demons? Nat Rev Cancer. 2003;3(5):339-49.
Campo-Trapero J, Cano-Sánchez J, Palacios-Sánchez B, Sánchez-Gutierrez JJ, González-Moles MA,
Bascones-Martínez A. Update on molecular pathology in oral cancer and precancer. Anticancer Res.
2008;28(2B):1197-205.
Cao Y, Li H, Deb S, Liu JP. TERT regulates cell survival independent of telomerase enzymatic activity.
Oncogene. 2002;21(20):3130-8.
Carroll VA, Ashcroft M. Regulation of angiogenic factors by HDM2 in renal cell carcinoma. Cancer Res.
2008;68(2):545-52.
Chakrabarti S, Dasgupta S, Roy S, Bhar A, Sengupta A, Roy A, et al. Microsatellite instability in
squamous cell carcinoma of head and neck from the Indian patient population. Int J Cancer.
2001;92(4):555-61.
Bibliography
185
Chakrobarty B, Roy JG, Majumdar S, Uppala D. Relationship among tobacco habits, human papilloma
virus (HPV) infection, p53 polymorphism/mutation and the risk of oral squamous cell carcinoma. J Oral
Maxillofac Pathol. 2014;18(2):211-6.
Chandra A, Sebastian BT, Agnihotri A. Oral squamous cell carcinoma pathogenesis and role of p53 protein.
Univ Res J Dent. 2013;3(3):128-30.
Chang MY, Chong IW, Chen FM, Wang JY, Cheng TL, Cheng YJ, et al. High frequency of frameshift
mutation on p53 gene in Taiwanese with non small cell lung cancer. Cancer Lett. 2005;222(2):195-204.
Chaves AC, Cherubini K, Herter N, Furian R, Santos DS, Squier C, et al. Characterization of p53 gene
mutations in a Brazilian population with oral squamous cell carcinomas. Int J Oncol. 2004;24(2):295-303.
Chen EI, Kridel SJ, Howard EW, Li W, Godzik A, Smith JW. A unique substrate recognition profile for
matrix metalloproteinase-2. J Biol Chem. 2002;277(6):4485-91.
Chen HH, Yu CH, Wang JT, Liu BY, Wang YP, Sun A, et al. Expression of human telomerase reverse
transcriptase (hTERT) protein is significantly associated with the progression, recurrence and prognosis of
oral squamous cell carcinoma in Taiwan. Oral Oncol. 2007;43(2):122-9.
Chen SF, Yu FS, Chang YC, Fu E, Nieh S, Lin YS. Role of human papillomavirus infection in
carcinogenesis of oral squamous cell carcinoma with evidences of prognostic association. J Oral Pathol
Med. 2012;41(1):9-15.
Chen X, Qiu J, Yang D, Lu J, Yan C, Zha X, et al. MDM2 promotes invasion and metastasis in invasive
ductal breast carcinoma by inducing matrix metalloproteinase-9. PLoS One. 2013;8(11):e78794.
Chen X, Sturgis EM, Lei D, Dahlstrom K, Wei Q, Li G. Human papillomavirus seropositivity synergizes
with MDM2 variants to increase the risk of oral squamous cell carcinoma. Cancer Res. 2010;70(18):7199-
208.
Cheng SJ, Lee JJ, Kok SH, Chou CH, Chang HH, Yang H, et al. Expression of vascular endothelial growth
factor is significantly associated with progression and prognosis of oral squamous cell carcinomas in
Taiwan. J Formos Med Assoc. 2011;110(1):50-7.
Chitra G, Chandramouli A, Chanchal C. P53 mutations in head and neck squamous cell carcinoma. Int J
Pharm Biomed Res. 2010;1(3):117-21.
Cho JH, Kim HS, Park CS, Kim JK, Jung KY, Shin BK, et al. Maspin expression in early oral tongue
cancer and its relation to expression of mutant-type p53 and vascular endothelial growth factor (VEGF).
Oral Oncol. 2007;43(3):272-7.
Chocolatewala NM, Chaturvedi P. Role of human papilloma virus in the oral carcinogenesis: an Indian
perspective. J Cancer Res Ther. 2009;5(2):71 - 7.
Choi S, Myers JN. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J
Dent Res. 2008;87(1):14-32.
Coelho KR. Challenges of the oral cancer burden in India. J Cancer Epidemiol. 2012;2012:701932.
Cortesina G, Martone T. Molecular metastases markers in head and neck squamous cell carcinoma: review
of the literature. Acta Otorhinolaryngol Ital. 2006;26(6):317-25.
Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, et al. Importance of TP53
codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer.
BMC Cancer. 2008;8:32.
Cukusić A, Skrobot Vidacek N, Sopta M, Rubelj I. Telomerase regulation at the crossroads of cell fate.
Cytogenet Genome Res. 2008;122(3-4):263-72.
da Silva SD, Ferlito A, Takes RP, Brakenhoff RH, Valentin MD, Woolgar JA, et al. Advances and
applications of oral cancer basic research. Oral Oncol. 2011;47(9):783-91.
Bibliography
186
da Silva SD, Hier M, Mlynarek A, Kowalski LP, Alaoui-Jamali MA. Recurrent oral cancer: current and
emerging therapeutic approaches. Front Pharmacol. 2012;3:149.
Dai D, Zhai W, Zhu T, Zhu H, Ling Y. Expression of telomerase reverse transcriptase and its relationship
with tumor suppressor gene p53 in HCC. Zhonghua Gan Zang Bing Za Zhi. 2001;9 (Suppl):79-81.
D'Costa J, Saranath D, Dedhia P, Sanghvi V, Mehta AR. Detection of HPV-16 genome in human oral
cancers and potentially malignant lesions from India. Oral Oncol. 1998;34(5):413-20.
de Vicente JC, Fresno MF, Villalain L, Vega JA, Hernández Vallejo G. Expression and clinical significance
of matrix metalloproteinase-2 and matrix metalloproteinase-9 in oral squamous cell carcinoma. Oral Oncol.
2005;41(3):283-93.
Deng Y, Chang S. Role of telomeres and telomerase in genomic instability, senescence and cancer. Lab
Invest. 2007;87(11):1071-6.
Denisov EV, Cherdyntseva NV, Litviakov NV, Malinovskaya EA, Babyshkina NN, Belyavskaya VA, et al.
TP53 Gene Polymorphisms in Cancer Risk: The Modulating Effect of Ageing, Ethnicity and TP53 Somatic
Abnormalities. TUMOR SUPPRESSOR GENES 2012:79.
Dharel N, Kato N, Muroyama R, Moriyama M, Shao RX, Kawabe T, et al. MDM2 promoter SNP309 is
associated with the risk of hepatocellular carcinoma in patients with chronic hepatitis C. Clin Cancer Res.
2006;12(16):4867-71.
Ducrest AL, Szutorisz H, Lingner J, Nabholz M. Regulation of the human telomerase reverse transcriptase
gene. Oncogene. 2002;21(4):541-52.
Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53
have markedly different apoptotic potential. Nat Genet. 2003;33(3):357-65.
Ebrahem Q, Chaurasia SS, Vasanji A, Qi JH, Klenotic PA, Cutler A, et al. Cross-talk between vascular
endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivo. Am
J Pathol. 2010;176(1):496-503.
Economopoulos KP, Sergentanis TN. Differential effects of MDM2 SNP309 polymorphism on breast
cancer risk along with race: a meta-analysis. Breast Cancer Res Treat. 2010;120(1):211-6.
Edwards D. Methods in molecular biology: minor errors in primer citations with major consequences: how
can we minimize these mistakes?–reply. Br J Cancer 2000;82(9):1612.
Elango KJ, Suresh A, Erode EM, Subhadradevi L, Ravindran HK, Iyer SK, et al. Role of human papilloma
virus in oral tongue squamous cell carcinoma. Asian Pac J Cancer Prev. 2011;12(4):889-96.
Eming SA, Krieg T. Molecular mechanisms of VEGF-A action during tissue repair. J Investig Dermatol
Symp Proc. 2006;11(1):79-86.
Erber R, Conradt C, Homann N, Enders C, Finckh M, Dietz A, et al. TP53 DNA contact mutations are
selectively associated with allelic loss and have a strong clinical impact in head and neck cancer. Oncogene.
1998;16(13):1671-9.
Faghani M, Ghasemi FM, Nikhbakht M, Salehi M. TP53 PIN3 polymorphism associated with breast cancer
risk in Iranian women. Indian J Cancer. 2011;48(3):298-302.
Falchetti ML, Pallini R, D'Ambrosio E, Pierconti F, Martini M, Cimino-Reale G, et al. In situ detection of
telomerase catalytic subunit mRNA in glioblastoma multiforme. Int J Cancer. 2000;88(6):895-901.
Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, et al. Matrix metalloproteinase-2 is
required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A.
2000;97(8):3884-9.
Bibliography
187
Farhang Ghahremani M, Goossens S, Nittner D, Bisteau X, Bartunkova S, Zwolinska A, et al. p53
promotes VEGF expression and angiogenesis in the absence of an intact p21-Rb pathway. Cell Death
Differ. 2013;20(7):888-97.
Faustino SE, Oliveira DT, Nonogaki S, Landman G, Carvalho AL, Kowalski LP. Expression of vascular
endothelial growth factor-C does not predict occult lymph-node metastasis in early oral squamous cell
carcinoma. Int J Oral Maxillofac Surg. 2008;37(4):372-8.
Feldser DM, Greider CW. Short telomeres limit tumor progression in vivo by inducing senescence. Cancer
Cell. 2007;11(5):461-9.
Felley-Bosco E, Weston A, Cawley HM, Bennett WP, Harris CC. Functional studies of a germ-line
polymorphism at codon 47 within the p53 gene. Am J Hum Genet. 1993;53(3):752-9.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12): 2893 - 917.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer
Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International
Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 14/march/2015
Ferry G, Lonchampt M, Pennel L, de Nanteuil G, Canet E, Tucker GC. Activation of MMP-9 by neutrophil
elastase in an in vivo model of acute lung injury. FEBS Lett. 1997;402(2-3):111-5.
Franchi A, Santucci M, Masini E, Sardi I, Paglierani M, Gallo O. Expression of matrix metalloproteinase 1,
matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neck. Cancer.
2002;95(9):1902-10.
Francisco G, Menezes PR, Eluf-Neto J, Chammas R. Arg72Pro TP53 polymorphism and cancer
susceptibility: a comprehensive meta-analysis of 302 case-control studies. Int J Cancer. 2011;129(4):920-
30.
Frank AK, Leu JI, Zhou Y, Devarajan K, Nedelko T, Klein-Szanto A, et al. The codon 72 polymorphism of
p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and
inflammation. Mol Cell Biol. 2011;31(6):1201-13.
Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26(12):1268-86.
Freier K, Pungs S, Flechtenmacher C, Bosch FX, Lichter P, Joos S, et al. Frequent high telomerase reverse
transcriptase expression in primary oral squamous cell carcinoma. J Oral Pathol Med. 2007;36(5):267-72.
Friedrich RE, Klapdor R, Hagel C, Bartel-Friedrich S. Vascular endothelial growth factor (VEGF) in sera
of oral and oropharyngeal squamous cell carcinoma patients. Anticancer Res. 2010;30(5):1765-6.
Fujimoto R, Kamata N, Yokoyama K, Ueda N, Satomura K, Hayashi E, et al. Expression of telomerase
components in oral keratinocytes and squamous cell carcinomas. Oral Oncol. 2001;37(2):132-40.
Gallì P, Cadoni G, Volante M, De Feo E, Amore R, Giorgio A, et al. A case-control study on the combined
effects of p53 and p73 polymorphisms on head and neck cancer risk in an Italian population. BMC Cancer.
2009;9:137.
Gandolfo M, Keszler A, Lanfranchi H, Itoiz ME. Increased subepithelial vascularization and VEGF
expression reveal potentially malignant changes in human oral mucosa lesions. Oral Surg Oral Med Oral
Pathol Oral Radiol Endod. 2011;111(4):486-93.
Gangane N, Chawla S, Anshu, Gupta SS, Sharma SM. Reassessment of risk factors for oral cancer. Asian
Pac J Cancer Prev. 2007;8(2):243-8.
Gauderman WJ, Morrison JM. QUANTO 1.1: A computer program for power and sample size calculations
for genetic-epidemiology studies, http://hydra.usc.edu/gxe, 2006.
Bibliography
188
Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutiérrez-Enríquez S, et al. A TP53
polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53
mRNA. Oncogene. 2004;23(10):1954-6.
George ML, Tutton MG, Janssen F, Arnaout A, Abulafi AM, Eccles SA, et al. VEGF-A, VEGF-C, and
VEGF-D in colorectal cancer progression. Neoplasia. 2001;3(5):420-7.
Gheit T, Vaccarella S, Schmitt M, Pawlita M, Franceschi S, Sankaranarayanan R, et al. Prevalence of
human papillomavirus types in cervical and oral cancers in central India. Vaccine. 2009;27(5):636-9.
Gogilashvili K, Shonia N, Burkadze G. The role of human papillomavirus in oral squamous cell carcinoma.
Georgian Med News. 2012;213:32-6.
Goodman JE, Mechanic LE, Luke BT, Ambs S, Chanock S, Harris CC. Exploring SNP-SNP interactions
and colon cancer risk using polymorphism interaction analysis. Int J Cancer. 2006;118(7):1790-7.
Grochola LF, Zeron-Medina J, Mériaux S, Bond GL. Single-nucleotide polymorphisms in the p53 signaling
pathway. Cold Spring Harb Perspect Biol. 2010;2(5):a001032.
Hadler-Olsen E, Winberg JO, Uhlin-Hansen L. Matrix metalloproteinases in cancer: their value as
diagnostic and prognostic markers and therapeutic targets. Tumour Biol. 2013;34(4):2041-51.
Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human
tumour cells with defined genetic elements. Nature. 1999;400(6743):464-8.
Hakeem AH, Pradhan SA, Tubachi J, Kannan R. Outcome of per oral wide excision of T1-2 N0 localized
squamous cell cancer of the buccal mucosa--analysis of 156 cases. Laryngoscope. 2013;123(1):177-80.
Halboub ES, Al-Anazi YM, Al-Mohaya MA. Characterization of Yemeni patients treated for oral and
pharyngeal cancers in Saudi Arabia. Saudi Med J. 2011;32(11):1177-82.
Hamid S, Yang YH, Peng KN, Ismail SM, Zain RB, Lim KP, et al. MDM2 SNP309 does not confer an
increased risk to oral squamous cell carcinoma but may modulate the age of disease onset. Oral Oncol.
2009;45(6):496-500.
Hatfield KJ, Reikvam H, Bruserud Ø. The crosstalk between the matrix metalloprotease system and the
chemokine network in acute myeloid leukemia. Curr Med Chem. 2010;17(36):4448-61.
Hayashi S, Watanabe J, Kawajiri K. Genetic polymorphisms in the 5’-flanking region change
transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem. 1991;110(4):559-65.
He M, Dong C, Ren R, Yuan D, Xie Y, Pan Y, et al. Radiation enhances the invasiveness of irradiated and
nonirradiated bystander hepatoma cells through a VEGF-MMP2 pathway initiated by p53. Radiat Res.
2013;180(4):389-97.
He Y, Karpanen T, Alitalo K. Role of lymphangiogenic factors in tumor metastasis. Biochim Biophys Acta.
2004;1654(1):3-12.
Heck JE, Berthiller J, Vaccarella S, Winn DM, Smith EM, Shan'gina O, et al. Sexual behaviours and the
risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology
(INHANCE) consortium. Int J Epidemiol. 2010;39(1):166-81.
Heinzel PA, Balaram P, Bernard HU. Mutations and polymorphisms in the p53, p21 and p16 genes in oral
carcinomas of Indian betel quid chewers. Int J Cancer. 1996;68(4):420-3.
Hervé MA, Buteau-Lozano H, Mourah S, Calvo F, Perrot-Applanat M. VEGF189 stimulates endothelial
cells proliferation and migration in vitro and up-regulates the expression of Flk-1/KDR mRNA. Exp Cell
Res. 2005;309(1):24-31.
Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial
growth factor and angiogenesis. Pharmacol Rev. 2004;56(4):549-80.
Bibliography
189
Hollborn M, Stathopoulos C, Steffen A, Wiedemann P, Kohen L, Bringmann A. Positive feedback
regulation between MMP-9 and VEGF in human RPE cells. Invest Ophthalmol Vis Sci. 2007;48(9):4360-7.
Hong B, van den Heuvel AP, Prabhu VV, Zhang S, El-Deiry WS. Targeting tumor suppressor p53 for
cancer therapy: strategies, challenges and opportunities. Curr Drug Targets. 2014;15(1):80-9.
Hong Q, Jun T, Lei J, Xiling J, Tamamura R. Expression and clinical significance of matrix
metalloproteinase-2 and its inhibitor TIMP-2 in oral squamous cell carcinoma. J Hard Tissue Biology.
2006;15(2):54-60.
Hopkins J, Cescon DW, Tse D, Bradbury P, Xu W, Ma C, et al. Genetic polymorphisms and head and neck
cancer outcomes: a review. Cancer Epidemiol Biomarkers Prev. 2008;17(3):490-9.
Houlston RS, Peto J. The search for low-penetrance cancer susceptibility alleles. Oncogene.
2004;23(38):6471-6.
Hrstka R, Beranek M, Klocova K, Nenutil R, Vojtesek B. Intronic polymorphisms in TP53 indicate lymph
node metastasis in breast cancer. Oncol Rep. 2009;22(5):1205-11.
Hsieh LL, Huang TH, Chen IH, Liao CT, Wang HM, Lai CH, et al. p53 polymorphisms associated with
mutations in and loss of heterozygosity of the p53 gene in male oral squamous cell carcinomas in Taiwan.
Br J Cancer. 2005;92(1):30-5.
Hsieh LL, Wang PF, Chen IH, Liao CT, Wang HM, Chen MC, et al. Characteristics of mutations in the p53
gene in oral squamous cell carcinoma associated with betel quid chewing and cigarette smoking in
Taiwanese. Carcinogenesis. 2001;22(9):1497-503.
Hu J, Chen C, Su Y, DU J, Qian X, Jin Y. Vascular endothelial growth factor promotes the expression of
cyclooxygenase 2 and matrix metalloproteinases in Lewis lung carcinoma cells. Exp Ther Med.
2012;4(6):1045-50.
Hu Z, Jin G, Wang L, Chen F, Wang X, Shen H. MDM2 promoter polymorphism SNP309 contributes to
tumor susceptibility: evidence from 21 case-control studies. Cancer Epidemiol Biomarkers Prev.
2007;16(12):2717-23.
Hu Z, Li C, Chen K, Wang LE, Sturgis EM, Spitz MR, et al. Single Nucleotide Polymorphisms in Selected
Apoptotic Genes and BPDE-Induced Apoptotic Capacity in Apparently Normal Primary Lymphocytes: A
Genotype-Phenotype Correlation Analysis. J Cancer Epidemiol. 2008: 2008: 147905.
Hu Z, Li X, Qu X, He Y, Ring BZ, Song E, et al. Intron 3 16 bp duplication polymorphism of TP53
contributes to cancer susceptibility: a meta-analysis. Carcinogenesis. 2010;31(4):643-7.
Huang SF, Chen IH, Liao CT, Wang HM, Liou SH, Hsieh LL. Combined effects of MDM2 SNP 309 and
p53 mutation on oral squamous cell carcinomas associated with areca quid chewing. Oral Oncol.
2009;45(1):16-22.
Huang X, Pateromichelakis S, Hills A, Sherriff M, Lyons A, Langdon J, et al. p53 mutations in deep tissues
are more strongly associated with recurrence than mutation-positive mucosal margins. Clin Cancer Res.
2007;13(20):6099-106.
Hutchings H, Ortega N, Plouët J. Extracellular matrix-bound vascular endothelial growth factor promotes
endothelial cell adhesion, migration, and survival through integrin ligation. FASEB J. 2003;17(11):1520-2.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100
B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012; 100(Pt B):1 - 441.
Ibayashi H, Pham TM, Fujino Y, Kubo T, Ozasa K, Matsuda S, Yoshimura T. Estimation of premature
mortality from oral cancer in Japan, 1995 and 2005. Cancer Epidemiol. 2011;35(4):342-4.
Jain N, Singh V, Hedau S, Kumar S, Daga MK, Dewan R, et al. Infection of human papillomavirus type 18
and p53 codon 72 polymorphism in lung cancer patients from India. Chest. 2005;128(6):3999-4007.
Bibliography
190
Janknecht R. On the road to immortality: hTERT upregulation in cancer cells. FEBS Lett. 2004;564(1-2):9-
13.
Jayalekshmi PA, Gangadharan P, Akiba S, Koriyama C, Nair RR. Oral cavity cancer risk in relation to
tobacco chewing and bidi smoking among men in Karunagappally, Kerala, India: Karunagappally cohort
study. Cancer Sci. 2011;102(2):460-7.
Jiang N, Pan J, Wang L, Duan YZ. No significant association between p53 codon 72 Arg/Pro
polymorphism and risk of oral cancer. Tumour Biol. 2013;34(1):587-96.
Jiang P, Liu J, Zeng X, Li W, Tang J. Association of TP53 codon 72 polymorphism with cervical cancer
risk in Chinese women. Cancer Genet Cytogenet. 2010;197(2):174-8.
Jin X, Beck S, Sohn YW, Kim JK, Kim SH, Yin J, et al. Human telomerase catalytic subunit (hTERT)
suppresses p53-mediated anti-apoptotic response via induction of basic fibroblast growth factor. Exp Mol
Med. 2010;42(8):574-82.
Jing G, Lv K, Jiao X. The p53 codon 72 polymorphism and the risk of oral cancer in a Chinese Han
population. Genet Test Mol Biomarkers. 2012;16(9):1149-52.
Johnstone S, Logan RM. The role of vascular endothelial growth factor (VEGF) in oral dysplasia and oral
squamous cell carcinoma. Oral Oncol. 2006;42(4):337-42.
Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. Overexpression of Mdm2 in mice reveals a
p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A. 1998;95(26):15608-12.
Joshi U, Modi B, Yadav S. A study on prevalence of chewing form of tobacco and existing quitting patterns
in urban population of jamnagar, gujarat. Indian J Community Med. 2010;35(1):105-8.
Kanaya T, Kyo S, Hamada K, Takakura M, Kitagawa Y, Harada H, et al. Adenoviral expression of p53
represses telomerase activity through down-regulation of human telomerase reverse transcriptase
transcription. Clin Cancer Res. 2000;6(4):1239-47.
Katara R, Singh N. Role of p53 in transcriptional regulation of proteases in mammals. Indian J of Med
Paediatr Oncol. 2008;29(4):19-22.
Katiyar S, Thelma BK, Murthy NS, Hedau S, Jain N, Gopalkrishna V, et al. Polymorphism of the p53
codon 72 Arg/Pro and the risk of HPV type 16/18-associated cervical and oral cancer in India. Mol Cell
Biochem. 2003;252(1-2):117-24.
Kato S, Han SY, Liu W, Otsuka K, Shibata H, Kanamaru R, et al. Understanding the function-structure and
function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation
analysis. Proc Natl Acad Sci U S A. 2003;100(14):8424-9.
Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment.
Cell. 2010;141(1):52-67.
Khaliq S, Hameed A, Khaliq T, Ayub Q, Qamar R, Mohyuddin A, et al. P53 mutations, polymorphisms,
and haplotypes in Pakistani ethnic groups and breast cancer patients. Genet Test. 2000;4(1):23-9.
Khan SA, Idrees K, Forslund A, Zeng Z, Rosenberg S, Pincas H, et al. Genetic variants in germline TP53
and MDM2 SNP309 are not associated with early onset colorectal cancer. J Surg Oncol. 2008;97(7):621-5.
Khan Z. An Overview of Oral Cancer in Indian Subcontinent and Recommendations to Decrease its
Incidence. WebmedCentral CANCER. 2012;3(8):WMC003626.
Khromova NV, Kopnin PB, Stepanova EV, Agapova LS, Kopnin BP. p53 hot-spot mutants increase tumor
vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway. Cancer Lett. 2009;276(2):143-
51.
Bibliography
191
Kim HR, Christensen R, Park NH, Sapp P, Kang MK, Park NH. Elevated expression of hTERT is
associated with dysplastic cell transformation during human oral carcinogenesis in situ. Clin Cancer Res.
2001;7(10):3079-86.
Kirkpatrick KL, Newbold RF, Mokbel K. The mRNA expression of hTERT in human breast carcinomas
correlates with VEGF expression. J Carcinog. 2004;3(1):1.
Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids.
2011;41(2):271-90.
Klozar J, Koslabova E, Kratochvil V, Salakova M, Tachezy R. Nodal status is not a prognostic factor in
patients with HPV-positive oral/oropharyngeal tumors. J Surg Oncol. 2013;107(6):625-33.
Knappskog S, Bjørnslett M, Myklebust LM, Huijts PE, Vreeswijk MP, Edvardsen H, et al. The MDM2
promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast
and ovarian cancer in Caucasians. Cancer Cell. 2011b;19(2):273-82.
Knappskog S, Lønning PE. Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription
factor binding and cancer risk. Transcription. 2011a;2(5):207-10.
Knappskog S, Lønning PE. MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk.
Oncotarget. 2011c;2(3):251-8.
Ko Y, Abel J, Harth V, Bröde P, Antony C, Donat S, et al. Association of CYP1B1 codon 432 mutant allele
in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer
Res. 2001;61(11):4398-404.
Koch WM, Lango M, Sewell D, Zahurak M, Sidransky D. Head and neck cancer in nonsmokers: a distinct
clinical and molecular entity. Laryngoscope. 1999;109(10):1544-51.
Kolkenbrock H, Hecker-Kia A, Orgel D, Kinawi A, Ulbrich N. Progelatinase B forms from human
neutrophils. complex formation of monomer/lipocalin with TIMP-1. Biol Chem. 1996;377(7-8):529-33.
Kono M, Watanabe M, Abukawa H, Hasegawa O, Satomi T, Chikazu D. Cyclo-oxygenase-2 expression is
associated with vascular endothelial growth factor C expression and lymph node metastasis in oral
squamous cell carcinoma. J Oral Maxillofac Surg. 2013;71(10):1694-702.
Koppikar P, deVilliers EM, Mulherkar R. Identification of human papillomaviruses in tumors of the oral
cavity in an Indian community. Int J Cancer. 2005;113(6):946-50.
Korzeniewski N, Spardy N, Duensing A, Duensing S. Genomic instability and cancer: lessons learned from
human papillomaviruses. Cancer Lett. 2011;305(2):113-22.
Kotra LP, Zhang L, Fridman R, Orlando R, Mobashery S. N-Glycosylation pattern of the zymogenic form
of human matrix metalloproteinase-9. Bioorg Chem. 2002;30(5):356-70.
Kozomara R, Jović N, Magić Z, Branković-Magić M, Minić V. p53 mutations and human papillomavirus
infection in oral squamous cell carcinomas: correlation with overall survival. J Craniomaxillofac Surg.
2005;33(5):342-8.
Krekac D, Brozkova K, Knoflickova D, Hrstka R, Muller P, Nenutil R, et al. MDM2SNP309 does not
associate with elevated MDM2 protein expression or breast cancer risk. Oncology. 2008;74(1-2):84-7.
Kridel SJ, Chen E, Kotra LP, Howard EW, Mobashery S, Smith JW. Substrate hydrolysis by matrix
metalloproteinase-9. J Biol Chem. 2001;276(23):20572-8.
Krishna Rao SV, Mejia G, Roberts-Thomson K, Logan R. Epidemiology of oral cancer in Asia in the past
decade--an update (2000-2012). Asian Pac J Cancer Prev. 2013;14(10):5567-77.
Kruaysawat W, Aekplakorn W, Chapman RS. Survival time and prognostic factors of oral cancer in Ubon
Ratchathani Cancer Center. J Med Assoc Thai. 2010;93(3):278-84.
Bibliography
192
Kulkarni SS, Kulkarni SS, Vastrad PP, Kulkarni BB, Markande AR, Kadakol GS, et al. Prevalence and
distribution of high risk human papillomavirus (HPV) Types 16 and 18 in Carcinoma of cervix, saliva of
patients with oral squamous cell carcinoma and in the general population in Karnataka, India. Asian Pac J
Cancer Prev. 2011;12(3):645-8.
Kumar SK, Zain RB, Ismail SM, Cheong SC. Human telomerase reverse transcriptase expression in oral
carcinogenesis--a preliminary report. J Exp Clin Cancer Res. 2005;24(4):639-46.
Kumaraswamy KL, Vidhya M. Human papilloma virus and oral infections: an update. J Cancer Res Ther.
2011;7(2):120 - 7.
Kuroda Y, Nakao H, Ikemura K, Katoh T. Association between the TP53 codon72 polymorphism and oral
cancer risk and prognosis. Oral Oncol. 2007;43(10):1043-8.
Kuropkat C, Plehn S, Herz U, Dünne AA, Renz H, Werner JA. Tumor marker potential of serum matrix
metalloproteinases in patients with head and neck cancer. Anticancer Res. 2002;22(4):2221-7.
Laco J, Nekvindova J, Novakova V, Celakovsky P, Dolezalova H, Tucek L, et al. Biologic importance and
prognostic significance of selected clinicopathological parameters in patients with oral and oropharyngeal
squamous cell carcinoma, with emphasis on smoking, protein p16(INK4a) expression, and HPV status.
Neoplasma. 2012;59(4):398-408.
Lai SR, Cunningham AP, Huynh VQ, Andrews LG, Tollefsbol TO. Evidence of extra-telomeric effects of
hTERT and its regulation involving a feedback loop. Exp Cell Res. 2007;313(2):322-30.
Lång A, Palmebäck Wegman P, Wingren S. The significance of MDM2 SNP309 and p53 Arg72Pro in
young women with breast cancer. Oncol Rep. 2009;22(3):575-9.
Lee BK, Diebel E, Neukam FW, Wiltfang J, Ries J. Diagnostic and prognostic relevance of expression of
human telomerase subunits in oral cancer. Int J Oncol. 2001;19(5):1063-8.
Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. Processing of VEGF-A by matrix
metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol.
2005;169(4):681-91.
Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev
Cancer. 2011;11(1):9-22.
Lehman TA, Haffty BG, Carbone CJ, Bishop LR, Gumbs AA, Krishnan S, et al. Elevated frequency and
functional activity of a specific germ-line p53 intron mutation in familial breast cancer. Cancer Res.
2000;60(4):1062-9.
Li C, Shintani S, Terakado N, Klosek SK, Ishikawa T, Nakashiro K, et al. Microvessel density and
expression of vascular endothelial growth factor, basic fibroblast growth factor, and platelet-derived
endothelial growth factor in oral squamous cell carcinomas. Int J Oral Maxillofac Surg. 2005;34(5):559-65.
Li H, Cao Y, Berndt MC, Funder JW, Liu JP. Molecular interactions between telomerase and the tumor
suppressor protein p53 in vitro. Oncogene. 1999;18(48):6785-94.
Liloglou T, Scholes AG, Spandidos DA, Vaughan ED, Jones AS, Field JK. p53 mutations in squamous cell
carcinoma of the head and neck predominate in a subgroup of former and present smokers with a low
frequency of genetic instability. Cancer Res. 1997;57(18):4070-4.
Lim KP, Sharifah H, Lau SH, Teo SH, Cheong SC. Alterations of the p14ARF-p53-MDM2 pathway in oral
squamous cell carcinoma: MDM2 overexpression is a common event. Oncol Rep. 2005;14(4):963-8.
Lin WJ, Jiang RS, Wu SH, Chen FJ, Liu SA. Smoking, alcohol, and betel quid and oral cancer: a
prospective cohort study. J Oncol. 2011;2011:525976.
Lindenbergh-van der Plas M, Brakenhoff RH, Kuik DJ, Buijze M, Bloemena E, Snijders PJ, et al.
Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma. Clin
Cancer Res. 2011;17(11):3733-41.
Bibliography
193
Liu J, Zhang C, Feng Z. Tumor suppressor p53 and its gain-of-function mutants in cancer. Acta Biochim
Biophys Sin (Shanghai). 2014;46(3):170-9.
Liu J, Zheng Y, Lei D, Liu D, Xu F, Jin T, et al. MDM2 309T>G polymorphism and risk of squamous cell
carcinomas of head and neck: a meta-analysis. Asian Pac J Cancer Prev. 2011;12(8):1899-903.
Liu X, Roberts J, Dakic A, Zhang Y, Schlegel R. HPV E7 contributes to the telomerase activity of
immortalized and tumorigenic cells and augments E6-induced hTERT promoter function. Virology.
2008;375(2):611-23.
Lorenzo JA, Pilbeam CC, Kalinowski JF, Hibbs MS. Production of both 92- and 72-kDa gelatinases by
bone cells. Matrix. 1992;12(4):282-90.
Loureiro RM, D'Amore PA. Transcriptional regulation of vascular endothelial growth factor in cancer.
Cytokine Growth Factor Rev. 2005;16(1):77-89.
Lozano G, Zambetti GP. What have animal models taught us about the p53 pathway? J Pathol.
2005;205(2):206-20.
Luzar B, Poljak M, Marin IJ, Eberlinc A, Klopcic U, Gale N. Human telomerase catalytic subunit gene re-
expression is an early event in oral carcinogenesis. Histopathology. 2004;45(1):13-9.
Ma'aita JK. Oral cancer in Jordan: a retrospective study of 118 patients. Croat Med J. 2000;41(1):64-9.
Madani AH, Dikshit M, Bhaduri D. Risk for oral cancer associated to smoking, smokeless and oral dip
products. Indian J Public Health. 2012;56(1):57-60.
Madani AH, Jahromi AS, Dikshit M, Bhaduri D. Risk assessment of tobacco types and oral cancer. Am J
Pharmacol Toxicol. 2010;5(1):9-13.
Maeda T, Matsumura S, Hiranuma H, Jikko A, Furukawa S, Ishida T, et al. Expression of vascular
endothelial growth factor in human oral squamous cell carcinoma: its association with tumour progression
and p53 gene status. J Clin Pathol. 1998;51(10):771-5.
Majumder PP. Ethnic populations of India as seen from an evolutionary perspective. J Biosci. 2001;26(4
Suppl):533-45.
Makwana NR, Shah VR, Yadav S. A study on prevalence of smoking and tobacco chewing among
adolescents in rural areas of Jamnagar district, Gujarat state. JMSR 2007;1(1):1-13.
Mannarini L, Kratochvil V, Calabrese L, Gomes Silva L, Morbini P, Betka J, et al. Human Papilloma Virus
(HPV) in head and neck region: review of literature. Acta Otorhinolaryngol Ital. 2009;29(3):119-26.
Mansfield L, Subramanian A, Devalia H, Jiang W, Newbold RF, Mokbel K. HTERT mRNA expression
correlates with matrix metalloproteinase-1 and vascular endothelial growth factor expression in human
breast cancer: a correlative study using RT-PCR. Anticancer Res. 2007;27(4B):2265-8.
Marcel V, Dichtel-Danjoy ML, Sagne C, Hafsi H, Ma D, Ortiz-Cuaran S, et al. Biological functions of p53
isoforms through evolution: lessons from animal and cellular models. Cell Death Differ. 2011;18(12):1815-
24.
Mărgăritescu C, Pirici D, Simionescu C, Mogoantă L, Raica M, Stîngă A, et al. VEGF and VEGFRs
expression in oral squamous cell carcinoma. Rom J Morphol Embryol. 2009;50(4):527-48.
Mărgăritescu C, Pirici D, Stîngă A, Simionescu C, Raica M, Mogoantă L, et al. VEGF expression and
angiogenesis in oral squamous cell carcinoma: an immunohistochemical and morphometric study. Clin Exp
Med. 2010;10(4):209-14.
Markopoulos AK. Current aspects on oral squamous cell carcinoma. Open Dent J. 2012;6:126-30.
Martin AC, Facchiano AM, Cuff AL, Hernandez-Boussard T, Olivier M, Hainaut P, et al. Integrating
mutation data and structural analysis of the TP53 tumor-suppressor protein. Hum Mutat. 2002;19(2):149-
64.
Bibliography
194
Martin J, Eynstone L, Davies M, Steadman R. Induction of metalloproteinases by glomerular mesangial
cells stimulated by proteins of the extracellular matrix. J Am Soc Nephrol. 2001;12(1):88-96.
Mattheij I, Pollock AM, Brhlikova P. Do cervical cancer data justify HPV vaccination in India?
Epidemiological data sources and comprehensiveness. J R Soc Med. 2012;105(6):250-62.
Mattu TS, Royle L, Langridge J, Wormald MR, Van den Steen PE, Van Damme J, et al. O-glycan analysis
of natural human neutrophil gelatinase B using a combination of normal phase-HPLC and online tandem
mass spectrometry: implications for the domain organization of the enzyme. Biochemistry.
2000;39(51):15695-704.
Miller DL, Puricelli MD, Stack MS. Virology and molecular pathogenesis of HPV (human papillomavirus)-
associated oropharyngeal squamous cell carcinoma. Biochem J. 2012;443(2):339-53.
Mishra A, Bharti AC, Varghese P, Saluja D, Das BC. Differential expression and activation of NF-kappaB
family proteins during oral carcinogenesis: Role of high risk human papillomavirus infection. Int J Cancer.
2006;119(12):2840-50.
Misra C, Majumder M, Bajaj S, Ghosh S, Roy B, Roychoudhury S. Polymorphisms at p53, p73, and
MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer. Mol Carcinog.
2009;48(9):790-800.
Mitra S, Chatterjee S, Panda CK, Chaudhuri K, Ray K, Bhattacharyya NP, et al. Haplotype structure of
TP53 locus in Indian population and possible association with head and neck cancer. Ann Hum Genet.
2003;67(1):26-34.
Mitra S, Sikdar N, Misra C, Gupta S, Paul RR, Roy B, et al. Risk assessment of p53 genotypes and
haplotypes in tobacco-associated leukoplakia and oral cancer patients from eastern India. Int J Cancer.
2005;117(5):786-93.
Mittal RD, George GP, Mishra J, Mittal T, Kapoor R. Role of functional polymorphisms of P53 and P73
genes with the risk of prostate cancer in a case-control study from Northern India. Arch Med Res.
2011;42(2):122-7.
Miyahara M, Tanuma J, Sugihara K, Semba I. Tumor lymphangiogenesis correlates with lymph node
metastasis and clinicopathologic parameters in oral squamous cell carcinoma. Cancer. 2007;110(6):1287-
94.
Mohtasham N, Babakoohi S, Shiva A, Shadman A, Kamyab-Hesari K, Shakeri MT, et al.
Immunohistochemical study of p53, Ki-67, MMP-2 and MMP-9 expression at invasive front of squamous
cell and verrucous carcinoma in oral cavity. Pathol Res Pract. 2013;209(2):110-4.
Mojtahedi Z, Hashemi SB, Khademi B, Karimi M, Haghshenas MR, Fattahi MJ, et al. p53 codon 72
polymorphism association with head and neck squamous cell carcinoma. Braz J Otorhinolaryngol.
2010;76(3):316-20.
Moll UM, Youngleib GL, Rosinski KB, Quigley JP. Tumor promoter-stimulated Mr 92,000 gelatinase
secreted by normal and malignant human cells: isolation and characterization of the enzyme from HT1080
tumor cells. Cancer Res. 1990;50(19):6162-70.
Moore JH. The ubiquitous nature of epistasis in determining susceptibility to common human diseases.
Hum Hered. 2003;56(1-3):73-82.
Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell.
2014;25(3):304-17.
Munirajan AK, Tutsumi-Ishii Y, Mohanprasad BK, Hirano Y, Munakata N, Shanmugam G, et al. p53 gene
mutations in oral carcinomas from India. Int J Cancer. 1996;66(3):297-300.
Muthumani P, Alagarsamy K, Dhandayuthapani S, Venkatesan T, Rathinavelu A. Pro-angiogenic effects of
MDM2 through HIF-1α and NF-κB mediated mechanisms in LNCaP prostate cancer cells. Mol Biol Rep.
2014;41(8):5533-41.
Bibliography
195
Muwonge R, Ramadas K, Sankila R, Thara S, Thomas G, Vinoda J, et al. Role of tobacco smoking,
chewing and alcohol drinking in the risk of oral cancer in Trivandrum, India: a nested case-control design
using incident cancer cases. Oral Oncol. 2008;44(5):446-54.
Nagpal JK, Patnaik S, Das BR. Prevalence of high-risk human papilloma virus types and its association
with P53 codon 72 polymorphism in tobacco addicted oral squamous cell carcinoma (OSCC) patients of
Eastern India. Int J Cancer. 2002;97(5):649-53.
Nair U, Bartsch H, Nair J. Alert for an epidemic of oral cancer due to use of the betel quid substitutes
gutkha and pan masala: a review of agents and causative mechanisms. Mutagenesis. 2004;19(4):251-62.
Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, et al. Telomerase
catalytic subunit homologs from fission yeast and human. Science. 1997;277(5328):955-9.
Nakashima M, Kondo S, Shimizu Y, Wakisaka N, Murono S, Furukawa M, et al. Impact of MDM2 single
nucleotide polymorphism on tumor onset in head and neck squamous cell carcinoma. Acta Otolaryngol.
2008;128(7):808-13.
Narasimhan M, Rose R, Karthikeyan M, Rathinavelu A. Detection of HDM2 and VEGF co-expression in
cancer cell lines: novel effect of HDM2 antisense treatment on VEGF expression. Life Sci. 2007;81(17-
18):1362-72.
Narasimhan M, Rose R, Ramakrishnan R, Zell JA, Rathinavelu A. Identification of HDM2 as a regulator of
VEGF expression in cancer cells. Life Sci. 2008;82(25-26):1231-41.
Nayak S, Goel MM, Chandra S, Bhatia V, Mehrotra D, Kumar S, et al. VEGF-A immunohistochemical and
mRNA expression in tissues and its serum levels in potentially malignant oral lesions and oral squamous
cell carcinomas. Oral Oncol. 2012;48(3):233-9.
Newbold RF. The significance of telomerase activation and cellular immortalization in human cancer.
Mutagenesis. 2002;17(6):539-50.
Nguyen M, Arkell J, Jackson CJ. Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol.
2001;33(10):960-70.
Niki T, Iba S, Tokunou M, Yamada T, Matsuno Y, Hirohashi S. Expression of vascular endothelial growth
factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin Cancer
Res. 2000;6(6):2431-9.
Obata A, Eura M, Sasaki J, Saya H, Chikamatsu K, Tada M, et al. Clinical significance of p53 functional
loss in squamous cell carcinoma of the oropharynx. Int J Cancer. 2000;89(2):187-93.
O-charoenrat P, Rhys-Evans P, Eccles SA. Expression of vascular endothelial growth factor family
members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer.
2001a;92(3):556-68.
O-Charoenrat P, Rhys-Evans PH, Eccles SA. Expression of matrix metalloproteinases and their inhibitors
correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol
Head Neck Surg. 2001b;127(7):813-20.
Ogmundsdóttir HM, Björnsson J, Holbrook WP. Role of TP53 in the progression of pre-malignant and
malignant oral mucosal lesions. A follow-up study of 144 patients. J Oral Pathol Med. 2009;38(7):565-71.
Oliveira DT, Faustino SE, Santos MJ, Nonogaki S, Landman G, Kowalski LP. Lymph Node Metastases in
Oral Cancer: Clinical Implication of the Vascular Endothelial Growth Factor-C Expression by Malignant
Cells. Austral - Asian Journal of Cancer. 2011;10 (4): 207-15.
Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol.
2010;2(2):a001107.
Ostwald C, Gogacz P, Hillmann T, Schweder J, Gundlach K, Kundt G, et al. p53 mutational spectra are
different between squamous-cell carcinomas of the lip and the oral cavity. Int J Cancer. 2000;88(1):82-6.
Bibliography
196
Overall CM, López-Otín C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat
Rev Cancer. 2002;2(9):657-72.
Ozeki C, Sawai Y, Shibata T, Kohno T, Okamoto K, Yokota J, et al. Cancer susceptibility polymorphism of
p53 at codon 72 affects phosphorylation and degradation of p53 protein. J Biol Chem. 2011;286(20):18251-
60.
Pal S, Datta K, Mukhopadhyay D. Central role of p53 on regulation of vascular permeability
factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res.
2001;61(18):6952-7.
Palani J, Lakshminarayanan V, Kannan R. Immunohistochemical detection of human telomerase reverse
transcriptase in oral cancer and pre-cancer. Indian J Dent Res. 2011;22(2):362.
Pandith AA, Shah ZA, Khan NP, Rasool R, Afroze D, Yousuf A, et al. Role of TP53 Arg72Pro
polymorphism in urinary bladder cancer predisposition and predictive impact of proline related genotype in
advanced tumors in an ethnic Kashmiri population. Cancer Genet Cytogenet. 2010;203(2):263-8.
Pannone G, De Maria S, Zamparese R, Metafora S, Serpico R, Morelli F, et al. Prognostic value of human
telomerase reverse transcriptase gene expression in oral carcinogenesis. Int J Oncol. 2007;30(6):1349-57.
Paquette B, Bisson M, Therriault H, Lemay R, Paré M, Banville P, et al. Activation of matrix
metalloproteinase-2 and -9 by 2- and 4-hydroxyestradiol. J Steroid Biochem Mol Biol. 2003;87(1):65-73.
Partridge M, Costea DE, Huang X. The changing face of p53 in head and neck cancer. Int J Oral Maxillofac
Surg. 2007;36(12):1123-38.
Partridge M, Li SR, Pateromichelakis S, Francis R, Phillips E, Huang XH, et al. Detection of minimal
residual cancer to investigate why oral tumors recur despite seemingly adequate treatment. Clin Cancer Res.
2000;6(7):2718-25.
Patel BP, Shah PM, Rawal UM, Desai AA, Shah SV, Rawal RM, et al. Activation of MMP-2 and MMP-9
in patients with oral squamous cell carcinoma. J Surg Oncol. 2005;90(2):81-8.
Patel BP, Shah SV, Shukla SN, Shah PM, Patel PS. Clinical significance of MMP-2 and MMP-9 in patients
with oral cancer. Head Neck. 2007 Jun;29(6):564-72.
Patel JA, Shah FG, Kothari JM, Patel KD. Prevalence of head and neck cancers in Ahmedabad, Gujarat.
Indian J Otolaryngol Head Neck Surg. 2009; 61(Suppl 1):4-10.
Patnaik S, Nayak BK, Das BR. Genetic alteration of p53 in oral tumors. In: Varma AK, ed.: Oral Oncology,
Vol. VI. New Delhi, India: Macmillan India Limited, 1999: 87-92.
Pei D, Weiss SJ. Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1
process progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem. 1996;271(15):9135-
40.
Peltonen JK, Helppi HM, Pääkkö P, Turpeenniemi-Hujanen T, Vähäkangas KH. p53 in head and neck
cancer: functional consequences and environmental implications of TP53 mutations. Head Neck Oncol.
2010;2:36.
Pereira AL, Veras SS, Silveira EJ, Seabra FR, Pinto LP, Souza LB, et al. The role of matrix extracellular
proteins and metalloproteinases in head and neck carcinomas: an updated review. Braz J Otorhinolaryngol.
2005;71(1):81-6.
Pérez-Sayáns M, Somoza-Martín JM, Barros-Angueira F, Reboiras-López MD, Gándara Rey JM, García-
García A. Genetic and molecular alterations associated with oral squamous cell cancer. Oncol Rep.
2009;22(6):1277-82.
Perrault SD, Hornsby PJ, Betts DH. Global gene expression response to telomerase in bovine adrenocortical
cells. Biochem Biophys Res Commun. 2005;335(3):925-36.
Bibliography
197
Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional
properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC
TP53 database. Hum Mutat. 2007;28(6):622-9.
Pietsch EC, Humbey O, Murphy ME. Polymorphisms in the p53 pathway. Oncogene. 2006;25(11):1602-11.
Pim D, Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int
J Cancer. 2004;108(2):196-9.
Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, et al. TP53 mutations and
survival in squamous-cell carcinoma of the head and neck. N Engl J Med. 2007;357(25):2552-61.
Post SM, Quintás-Cardama A, Pant V, Iwakuma T, Hamir A, Jackson JG, et al. A high-frequency
regulatory polymorphism in the p53 pathway accelerates tumor development. Cancer Cell. 2010;18(3):220-
30.
Powell E, Piwnica-Worms D, Piwnica-Worms H. Contribution of p53 to metastasis. Cancer Discov. 2014:
4(4): 405-14.
Priya SR, D'Cruz AK, Pai PS. Cut margins and disease control in oral cancers. J Cancer Res Ther.
2012;8(1):74-9.
Qi DL, Ohhira T, Fujisaki C, Inoue T, Ohta T, Osaki M, et al. Identification of PITX1 as a TERT
suppressor gene located on human chromosome 5. Mol Cell Biol. 2011;31(8):1624-36.
Qin G, Kishore R, Dolan CM, Silver M, Wecker A, Luedemann CN, et al. Cell cycle regulator E2F1
modulates angiogenesis via p53-dependent transcriptional control of VEGF. Proc Natl Acad Sci U S A.
2006;103(29):11015-20.
Ragin CC, Modugno F, Gollin SM. The epidemiology and risk factors of head and neck cancer: a focus on
human papillomavirus. J Dent Res. 2007;86(2):104-14.
Rahman R, Latonen L, Wiman KG. hTERT antagonizes p53-induced apoptosis independently of
telomerase activity. Oncogene. 2005;24(8):1320-7.
Ralhan R, Agarwal S, Nath N, Mathur M, Wasylyk B, Srivastava A. Correlation between p53 gene
mutations and circulating antibodies in betel- and tobacco-consuming North Indian population. Oral Oncol.
2001;37(3):243-50.
Ram H, Sarkar J, Kumar H, Konwar R, Bhatt ML, Mohammad S. Oral cancer: risk factors and molecular
pathogenesis. J Maxillofac Oral Surg. 2011;10(2):132-7.
Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res.
2002;30(17):3894-900.
Ranuncolo SM, Matos E, Loria D, Vilensky M, Rojo R, Bal de Kier Joffé E, et al. Circulating 92-kilodalton
matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck
squamous cell carcinoma. Cancer. 2002;94(5):1483-91.
Rathinavelu A, Narasimhan M, Muthumani P. A novel regulation of VEGF expression by HIF-1α and
STAT3 in HDM2 transfected prostate cancer cells. J Cell Mol Med. 2012;16(8):1750-7.
Rautava J, Syrjänen S. Biology of human papillomavirus infections in head and neck carcinogenesis. Head
Neck Pathol. 2012;6 (Suppl 1):S3-15.
Raval GN, Patel DD, Sainger RN, Shah MH, Shah JS, Patel MM, et al. A Study of Various
Sociodemographic Factors and Plasma Vitamin Levels in Oral and Pharyngeal Cancer in Gujarat, India.
Asian Pac J Cancer Prev. 2001;2(3):215-24.
Raval GN, Sainger RN, Rawal RM, Patel JB, Patel BP, Jha FP, et al. Vitamin B(12) and Folate Status in
Head and Neck Cancer. Asian Pac J Cancer Prev. 2002;3(2):155-62.
Bibliography
198
Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 Tumor Suppressor Gene: Important Milestones
at the Various Steps of Tumorigenesis. Genes Cancer. 2011;2(4):466-74.
Rodríguez D, Morrison CJ, Overall CM. Matrix metalloproteinases: what do they not do? New substrates
and biological roles identified by murine models and proteomics. Biochim Biophys Acta. 2010;1803(1):39-
54.
Rogler A, Rogenhofer M, Borchardt A, Lunz JC, Knoell A, Hofstaedter F, et al. P53 codon 72 (Arg72Pro)
polymorphism and prostate cancer risk: association between disease onset and proline genotype.
Pathobiology. 2011;78(4):193-200.
Rollin J, Régina S, Vourc'h P, Iochmann S, Bléchet C, Reverdiau P, et al. Influence of MMP-2 and MMP-9
promoter polymorphisms on gene expression and clinical outcome of non-small cell lung cancer. Lung
Cancer. 2007;56(2):273-80.
Roomi MW, Monterrey JC, Kalinovsky T, Rath M, Niedzwiecki A. Patterns of MMP-2 and MMP-9
expression in human cancer cell lines. Oncol Rep. 2009;21(5):1323-33.
Roos G, Nilsson P, Cajander S, Nielsen NH, Arnerlöv C, Landberg G. Telomerase activity in relation to
p53 status and clinico-pathological parameters in breast cancer. Int J Cancer. 1998;79(4):343-8.
Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets
in human cancer. J Clin Oncol. 2009;27(31):5287-97.
Royds JA, Iacopetta B. p53 and disease: when the guardian angel fails. Cell Death Differ. 2006;13(6):1017-
26.
Rudd PM, Mattu TS, Masure S, Bratt T, Van den Steen PE, Wormald MR, Küster B, et al. Glycosylation of
natural human neutrophil gelatinase B and neutrophil gelatinase B-associated lipocalin. Biochemistry.
1999;38(42):13937-50.
Ruokolainen H, Pääkkö P, Turpeenniemi-Hujanen T. Tissue and circulating immunoreactive protein for
MMP-2 and TIMP-2 in head and neck squamous cell carcinoma--tissue immunoreactivity predicts
aggressive clinical course. Mod Pathol. 2006;19(2):208-17.
Ruutu M, Peitsaro P, Johansson B, Syrjänen S. Transcriptional profiling of a human papillomavirus 33-
positive squamous epithelial cell line which acquired a selective growth advantage after viral integration.
Int J Cancer. 2002;100(3):318-26.
Sagne C, Marcel V, Amadou A, Hainaut P, Olivier M, Hall J. A meta-analysis of cancer risk associated
with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects.
Cell Death Dis. 2013;4:e492.
Saini R, Tang TH, Zain RB, Cheong SC, Musa KI, Saini D, et al. Significant association of high-risk
human papillomavirus (HPV) but not of p53 polymorphisms with oral squamous cell carcinomas in
Malaysia. J Cancer Res Clin Oncol. 2011;137(2):311-20.
Salvioli S, Bonafé M, Barbi C, Storci G, Trapassi C, Tocco F, et al. p53 codon 72 alleles influence the
response to anticancer drugs in cells from aged people by regulating the cell cycle inhibitor p21WAF1. Cell
Cycle. 2005;4(9):1264-71.
Sam KK, Gan CP, Yee PS, Chong CE, Lim KP, Karen-Ng LP, et al. Novel MDM2 splice variants
identified from oral squamous cell carcinoma. Oral Oncol. 2012;48(11):1128-35.
Sanchez-Carbayo M, Socci ND, Kirchoff T, Erill N, Offit K, Bochner BH, et al. A polymorphism in HDM2
(SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive
bladder cancer. Clin Cancer Res. 2007;13(11):3215-20.
Saranath D, Tandle AT, Teni TR, Dedhia PM, Borges AM, Parikh D, et al. p53 inactivation in chewing
tobacco-induced oral cancers and leukoplakias from India. Oral Oncol. 1999;35(3):242-50.
Bibliography
199
Sato H, Kinoshita T, Takino T, Nakayama K, Seiki M. Activation of a recombinant membrane type 1-
matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor of
metalloproteinases (TIMP)-2. FEBS Lett. 1996;393(1):101-4.
Scully C. Oral cancer aetiopathogenesis; past, present and future aspects. Med Oral Patol Oral Cir Bucal.
2011;16(3):e306-11.
Shah FD, Shukla SN, Shah PM, Shukla HK, Patel PS. Clinical significance of matrix metalloproteinase 2
and 9 in breast cancer. Indian J Cancer. 2009;46(3):194-202.
Shang ZJ, Li JR, Li ZB. Upregulation of serum and tissue vascular endothelial growth factor correlates with
angiogenesis and prognosis of oral squamous cell carcinoma. J Oral Maxillofac Surg. 2007;65(1):17-21.
Shats I, Milyavsky M, Tang X, Stambolsky P, Erez N, Brosh R, et al. p53-dependent down-regulation of
telomerase is mediated by p21waf1. J Biol Chem. 2004;279(49):50976-85.
Shen H, Zheng Y, Sturgis EM, Spitz MR, Wei Q. P53 codon 72 polymorphism and risk of squamous cell
carcinoma of the head and neck: a case-control study. Cancer Lett. 2002;183(2):123-30.
Sherin N, Simi T, Shameena P, Sudha S. Changing trends in oral cancer. Indian J Cancer. 2008;45(3):93-6.
Shi Q, Xiao K, Wei W, Zhang BY, Chen C, Xu Y, et al. Associations of TP53 mutations, codon 72
polymorphism and human papillomavirus in head and neck squamous cell carcinoma patients. Oncol Rep.
2013;30(6):2811-9.
Shinohara A, Sakano S, Hinoda Y, Nishijima J, Kawai Y, Misumi T, et al. Association of TP53 and MDM2
polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy. Cancer Sci.
2009;100(12):2376-82.
Shintani S, Li C, Ishikawa T, Mihara M, Nakashiro K, Hamakawa H. Expression of vascular endothelial
growth factor A, B, C, and D in oral squamous cell carcinoma. Oral Oncol. 2004;40(1):13-20.
Shukla S, Bharti AC, Mahata S, Hussain S, Kumar R, Hedau S, et al. Infection of human papillomaviruses
in cancers of different human organ sites. Indian J Med Res. 2009;130(3):222-33.
Shwe M, Chiguchi G, Yamada S, Nakajima T, Maung KK, Takagi M, et al. P53 and MDM2 co-expression
in tobacco and betel chewing-associated oral squamous cell carcinomas. J Med Dent Sci. 2001;48(4):113-9.
Siegelmann-Danieli N, Ben-Izhack O, Hanlon A, Ridge JA, Stein ME, Khandelwal V, et al. P53 alteration
in oral tongue cancer is not significantly associated with age at diagnosis or tobacco exposure. Tumori.
2005;91(4):346-50.
Sina M, Pedram M, Ghojazadeh M, Kochaki A, Aghbali A. P53 gene codon 72 polymorphism in patients
with oral squamous cell carcinoma in the population of northern Iran. Med Oral Patol Oral Cir Bucal.
2014;19(6):e550-5.
Singh RD, Haridas N, Patel JB, Shah FD, Shukla SN, Shah PM, et al. Matrix metalloproteinases and their
inhibitors: correlation with invasion and metastasis in oral cancer. Indian J Clin Biochem. 2010;25(3):250-
9.
Singh V, Rastogi N, Mathur N, Singh K, Singh MP. Association of polymorphism in MDM-2 and p53
genes with breast cancer risk in Indian women. Ann Epidemiol. 2008;18(1):48-57.
Sinha P, Logan HL, Mendenhall WM. Human papillomavirus, smoking, and head and neck cancer. Am J
Otolaryngol. 2012;33(1):130-6.
Smith EM, Rubenstein LM, Haugen TH, Pawlita M, Turek LP. Complex etiology underlies risk and
survival in head and neck cancer human papillomavirus, tobacco, and alcohol: a case for multifactor
disease. J Oncol. 2012;2012:571862.
Bibliography
200
Śnietura M, Jaworska M, Pigłowski W, Goraj-Zając A, Woźniak G, Lange D. High-risk HPV DNA status
and p16 (INK4a) expression as prognostic markers in patients with squamous cell cancer of oral cavity and
oropharynx. Pol J Pathol. 2010;61(3):133-9.
Sommer T, Olofsson J. Significance of p53, PCNA and Ki-67 in the prognosis of squamous cell carcinoma
of the oral cavity. Laryngorhinootologie. 1997;76(3):189-96.
Sorsa T, Salo T, Koivunen E, Tyynelä J, Konttinen YT, Bergmann U, et al. Activation of type IV
procollagenases by human tumor-associated trypsin-2. J Biol Chem. 1997;272(34):21067-74.
Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population
data. Am J Hum Genet. 2001;68(4):978-89.
Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol.
2001;17:463-516.
Stimpfl M, Tong D, Fasching B, Schuster E, Obermair A, Leodolter S, et al. Vascular endothelial growth
factor splice variants and their prognostic value in breast and ovarian cancer. Clin Cancer Res.
2002;8(7):2253-9.
Subapriya R, Thangavelu A, Mathavan B, Ramachandran CR, Nagini S. Assessment of risk factors for oral
squamous cell carcinoma in Chidambaram, Southern India: a case-control study. Eur J Cancer Prev.
2007;16(3):251-6.
Sugiura T, Inoue Y, Matsuki R, Ishii K, Takahashi M, Abe M, et al. VEGF-C and VEGF-D expression is
correlated with lymphatic vessel density and lymph node metastasis in oral squamous cell carcinoma:
Implications for use as a prognostic marker. Int J Oncol. 2009;34(3):673-80.
Syrjänen K, Syrjänen S, Lamberg M, Pyrhönen S, Nuutinen J. Morphological and immunohistochemical
evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. Int J
Oral Surg. 1983;12(6):418-24.
Tae K, El-Naggar AK, Yoo E, Feng L, Lee JJ, Hong WK, et al. Expression of vascular endothelial growth
factor and microvessel density in head and neck tumorigenesis. Clin Cancer Res. 2000;6(7):2821-8.
Tandle AT, Sanghvi V, Saranath D. Determination of p53 genotypes in oral cancer patients from India. Br J
Cancer. 2001;84(6):739-42.
Tang F, Gu DH, Wang H, Zhu TF, Zhu HG, Xu ZD, et al. Expression and significance of hTERT mRNA in
breast carcinoma and its relation to p53. Zhonghua Zhong Liu Za Zhi. 2006;28(3):192-5.
Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell.
2008;133(4):612-26.
Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Serum vascular endothelial growth
factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer. Cancer Invest.
2006;24(6):576-80.
Thode C, Bilde A, Von Buchwald C, Dabelsteen E.TP53 mutations in clinically normal mucosa adjacent to
oral carcinomas.J Oral Pathol Med. 2010;39(9):662-6.
Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-
type p53 differ biochemically and biologically. Mol Cell Biol. 1999;19(2):1092-100.
Toh WH, Kyo S, Sabapathy K. Relief of p53-mediated telomerase suppression by p73. J Biol Chem.
2005;280(17):17329-38.
Tsuji T, Mimura Y, Wen S, Li X, Kanekawa A, Sasaki K, et al. The significance of PCNA and p53 protein
in some oral tumors. Int J Oral Maxillofac Surg. 1995;24(3):221-5.
Bibliography
201
Tu HF, Chen HW, Kao SY, Lin SC, Liu CJ, Chang KW. MDM2 SNP 309 and p53 codon 72
polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative
irradiation. Radiother Oncol. 2008;87(2):243-52.
Ugarte-Berzal E, Redondo-Muñoz J, Eroles P, Del Cerro MH, García-Marco JA, Terol MJ, et al.
VEGF/VEGFR2 interaction down-regulates matrix metalloproteinase-9 via STAT1 activation and inhibits
B chronic lymphocytic leukemia cell migration. Blood. 2010;115(4):846-9.
Valentin-Vega YA, Barboza JA, Chau GP, El-Naggar AK, Lozano G. High levels of the p53 inhibitor
MDM4 in head and neck squamous carcinomas. Hum Pathol. 2007;38(10):1553-62.
van Houten VM, Leemans CR, Kummer JA, Dijkstra J, Kuik DJ, van den Brekel MW, et al. Molecular
diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study.
Clin Cancer Res. 2004;10(11):3614-20.
van Houten VM, Tabor MP, van den Brekel MW, Kummer JA, Denkers F, Dijkstra J, et al. Mutated p53 as
a molecular marker for the diagnosis of head and neck cancer. J Pathol. 2002;198(4):476-86.
Vazquez A, Bond EE, Levine AJ, Bond GL. The genetics of the p53 pathway, apoptosis and cancer
therapy. Nat Rev Drug Discov. 2008;7(12):979-87.
Vilen ST, Salo T, Sorsa T, Nyberg P. Fluctuating roles of matrix metalloproteinase-9 in oral squamous cell
carcinoma. ScientificWorldJournal. 2013;2013:920595.
Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure,
function, and biochemistry. Circ Res. 2003;92(8):827-39.
Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53. Cell. 2009;137(3):413-31.
Wan Y, Wu W, Yin Z, Guan P, Zhou B. MDM2 SNP309, gene-gene interaction, and tumor susceptibility:
an updated meta-analysis. BMC Cancer. 2011;11:208.
Wang W, Han S, Yao Z, Li X, Huang P, Zhang M, et al. A study of epidemiologic and recurrence factors of
oral cancer. J Oral Maxillofac Surg. 2012;70(9):2205-10.
Wang Y, Zhang YX, Kong CZ, Zhang Z, Zhu YY. Loss of P53 facilitates invasion and metastasis of
prostate cancer cells. Mol Cell Biochem. 2013;384(1-2):121-7.
Wang-Gohrke S, Weikel W, Risch H, Vesprini D, Abrahamson J, Lerman C, et al. Intron variants of the
p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2
germline mutations. Br J Cancer. 1999;81(1):179-83.
Warburton G, Nikitakis NG, Roberson P, Marinos NJ, Wu T, Sauk JJ Jr, et al. Histopathological and
lymphangiogenic parameters in relation to lymph node metastasis in early stage oral squamous cell
carcinoma. J Oral Maxillofac Surg. 2007;65(3):475-84.
Wen Y, Yu D, Wang C, Li L, Wang X, Tang X, et al. Expression of VEGF-C and its correlation with
cervical lymph nodes metastasis of oral cancers. Hua Xi Kou Qiang Yi Xue Za Zhi. 2001;19(1):5-8.
Weston A, Wolff MS, Morabia A. True extended haplotypes of p53: indicators of breast cancer risk. Cancer
Genet Cytogenet. 1998;102(2):153-4.
Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer.
2009;9(2):95-107.
Wisman GB, Hollema H, Helder MN, Knol AJ, Van der Meer GT, Krans M, et al. Telomerase in relation to
expression of p53, c-Myc and estrogen receptor in ovarian tumours. Int J Oncol. 2003;23(5):1451-9.
Wo X, Han D, Sun H, Liu Y, Meng X, Bai J, et al. MDM2 SNP309 contributes to tumor susceptibility: a
meta-analysis. J Genet Genomics. 2011;38(8):341-50.
Wolf CR. Metabolic factors in cancer susceptibility. Cancer Surv. 1990;9(3):437-74.
Bibliography
202
Woolard J, Bevan HS, Harper SJ, Bates DO. Molecular diversity of VEGF-A as a regulator of its biological
activity. Microcirculation. 2009;16(7):572-92.
Wu GY, Zhu L, Feng ZQ, Peng T, Qi B. The expression of hTERT and p53 protein in pre-malignant and
malignant lesions of human oral mucosa. Shanghai Kou Qiang Yi Xue. 2005;14(1):51-4.
Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, et al. p53 Genotypes and Haplotypes Associated
With Lung Cancer Susceptibility and Ethnicity. J Natl Cancer Inst. 2002;94(9):681-90.
www-p53.iarc.fr
Xiong J, Yang Q, Li J, Zhou S. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated
tumor angiogenesis in human breast cancer. Angiogenesis. 2014;17(1):37-50.
Yamazaki Y, Chiba I, Hirai A, Sugiura C, Notani K, Kashiwazaki H, et al. Specific p53 mutations predict
poor prognosis in oral squamous cell carcinoma. Oral Oncol. 2003;39(2):163-9.
Yan BZ, Wang J, Zhang B, Dong FS, Hou L, Wang X. Inhibitory effect of p53 gene on telomerase activity
and proliferative activity in salivary adenoid cystic carcinoma cells. Zhonghua Kou Qiang Yi Xue Za Zhi.
2006;41(1):45-8.
Yana I, Weiss SJ. Regulation of membrane type-1 matrix metalloproteinase activation by proprotein
convertases. Mol Biol Cell. 2000;11(7):2387-401.
Yang J, Gao W, Song NH, Wang W, Zhang JX, Lu P, et al. The risks, degree of malignancy and clinical
progression of prostate cancer associated with the MDM2 T309G polymorphism: a meta-analysis. Asian J
Androl. 2012;14(5):726-31.
Yarden RI, Friedman E, Metsuyanim S, Olender T, Ben-Asher E, Papa MZ. MDM2 SNP309 accelerates
breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Breast
Cancer Res Treat. 2008;111(3):497-504.
Yavrouian EJ, Sinha UK. Recent advances in biomarkers and potential targeted therapies in head and neck
squamous cell carcinoma. ISRN Surg 2012;2012:715743.
Yoshioka Y, Shimizu S, Ito T, Taniguchi M, Nomura M, Nishida T, et al. p53 inhibits vascular endothelial
growth factor expression in solid tumor. J Surg Res. 2012;174(2):291-7.
Yu DH, Wen YM, Sun JD, Wei SL, Xie HP, Pang FH. Relationship among expression of vascular
endothelial growth factor-C(VEGF-C), angiogenesis, lymphangiogenesis, and lymphatic metastasis in oral
cancer. Ai Zheng. 2002;21(3):319-22.
Yu H, Huang YJ, Liu Z, Wang LE, Li G, Sturgis EM, et al. Effects of MDM2 promoter polymorphisms and
p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck. Mol
Carcinog. 2011;50(9):697-706.
Yuan A, Yu CJ, Luh KT, Kuo SH, Lee YC, Yang PC. Aberrant p53 expression correlates with expression
of vascular endothelial growth factor mRNA and interleukin-8 mRNA and neoangiogenesis in non-small-
cell lung cancer. J Clin Oncol. 2002;20(4):900-10.
Zacchigna S, Pattarini L, Zentilin L, Moimas S, Carrer A, Sinigaglia M, et al. Bone marrow cells recruited
through the neuropilin-1 receptor promote arterial formation at the sites of adult neoangiogenesis in mice. J
Clin Invest. 2008;118(6):2062-75.
Zhao D, Xu QG, Chen XM, Fan MW. Human papillomavirus as an independent predictor in oral squamous
cell cancer. Int J Oral Sci. 2009;1(3):119-25.
Zhou CX, Gao Y, Johnson NW, Gao J. Immunoexpression of matrix metalloproteinase-2 and matrix
metalloproteinase-9 in the metastasis of squamous cell carcinoma of the human tongue. Aust Dent J.
2010;55(4):385-9.
Bibliography
203
Zhou J, Ding D, Wang M, Cong YS. Telomerase reverse transcriptase in the regulation of gene expression.
BMB Rep. 2014;47(1):8-14.
Zhou S, Gu L, He J, Zhang H, Zhou M. MDM2 regulates vascular endothelial growth factor mRNA
stabilization in hypoxia. Mol Cell Biol. 2011;31(24):4928-37.
Zhu F, Dollé ME, Berton TR, Kuiper RV, Capps C, Espejo A, et al. Mouse models for the p53 R72P
polymorphism mimic human phenotypes. Cancer Res. 2010;70(14):5851-9.
Zhuo XL, Li Q, Zhou Y, Cai L, Xiang ZL, Yuan W, et al. Study on TP53 codon 72 polymorphisms with
oral carcinoma susceptibility. Arch Med Res. 2009;40(7):625-34.
Zietz C, Rössle M, Haas C, Sendelhofert A, Hirschmann A, Stürzl M, et al. MDM-2 oncoprotein
overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol.
1998;153(5):1425-33.
Zucker S, Pei D, Cao J, Lopez-Otin C. Membrane type-matrix metalloproteinases (MT-MMP). Curr Top
Dev Biol. 2003;54:1-74.
